A bit more would be good.
In this case, a summary of the problem:
Because the society has to limit the use of new antibiotics in order to avoid the rise of antibiotics resistance to them (keeping them as “weapons of last resort”), the side effect of that is that the creators of new antibiotics don’t make any meaningful money and only suffer financial losses from those undertakings.
So pharma stopped developing new antibiotics.
This is what needs to be fixed.
I read this and don't really agree.
First, I feel your analogy between the two case studies is lacking. Antibiotics are often toxic, and the more toxic the antibiotic, the more likely it will be withheld from frontline treatment. Amikacin (the successful drug in the article) is a beta-lactam, which, as a class, generally have few issues with toxicity since they attack cell walls, which humans do not have. Plazomicin (the failed drug) is an aminoglycoside, which attacks protein synthesis and, unfortunately, humans also synthesize proteins, so there are many side effects and aminoglycosides are more toxic and generally discouraged from usage.
Kanamycin, the ancestor of amikacin, was a frontline antibiotic and now discontinued: still approved by the FDA, but no longer made because we have better antibiotics. Sisomycin, the ancestor to plazomycin, has never been approved by the FDA for treatment due to high toxicity and the existence of better last-resort antibiotics (like colistin).
So of course an antibiotic derived from a popular frontline antibiotic with a low toxicity profile would outsell a toxic antibiotic derived from an even more toxic ancestor destined to be last-resort even before it hits the market.
--
Secondly, isn't the current state of affairs free market working as intended? There is no (current) demand for new antibiotics, so of course developing new antibiotics is a losing proposition. Sure, we can predict that in the future there may be a greater demand for antibiotics but developing a new antibiotic now will likely lose you money, unless you can time it that the demand for antibiotics rises before your patent expires.
I would guess developing a novel low toxicity antibiotic would immediately make tonnes of money, so the demand is still there, it's just that the antibiotics that are being developed don't match the profile for useful antibiotic for which there is demand. If such antibiotics exist but are being held back to slow antibiotic resistance, then the problem won't be solved by giving more money to corporations, since the choice we've made is to trade x lives per year to slow the evolution of antibiotic resistance which, in turn, slows demand.
My posts will be on Substack and I will share excerpts of my book through linkposts.
I'm working on a book that discusses the economics of innovation and changemaking because even philanthropic endeavors need to assess the flow of money to be viable. This excerpt discusses the antibiotic market.